Objective Rapid eye movement (REM) sleep behavior disorder (RBD) is a parasomnia frequently affecting patients with synucleinopathies, but its exact prevalence in multiple system atrophy (MSA) is unclear. Whether questionnaires alone are sufficient to diagnose RBD is also unknown. Methods We performed a cross-sectional study of patients with probable MSA from six academic centers in the US and Europe. RBD was ascertained clinically and with polysomnography; we also performed a meta-analysis according to PRISMA guidelines for studies published before September 2014 that reported the prevalence of RBD in MSA. A random-effects model was constructed using weighted prevalence proportions. Only articles in English were included. Studies were classified into those that ascertained the presence of RBD in MSA clinically and with polysomnography. Case reports or case series (B5 patients) were not included. Results Forty-two patients completed questionnaires and underwent polysomnography. Of those, 32 (76.1 %) had clinically suspected RBD and 34 (81 %) had polysomnography-confirmed RBD. Two patients reported no symptoms of RBD but had polysomnography-confirmed RBD. The primary search strategy yielded 374 articles of which 12 met the inclusion criteria. The summary prevalence of clinically suspected RBD was 73 % (95 % CI, 62-84 %) in a combined sample of 324 MSA patients. The summary prevalence of polysomnography-confirmed RBD was 88 % (95 % CI, 79-94 %) in a combined sample of 217 MSA patients. Interpretation Polysomnography-confirmed RBD is present in up to 88 % of patients with MSA. RBD was present in some patients that reported no symptoms. More than half of MSA patients report symptoms of RBD before the onset of motor deficits.
Introduction
Normal sleep is divided into periods with and without rapid eye movements (i.e., REM and non-REM sleep). During REM sleep, normally about 20 % of total sleep time, skeletal muscle tone is lost (i.e., atonia) and subjects are immobile except for their eyes. Dreams usually occur during these periods of REM sleep.
The inhibition of muscle tone during REM sleep requires the activity of pontomedullary brainstem nuclei [9, 24] . Lesions affecting these neurons result in a peculiar parasomnia named REM sleep behavior disorder (RBD). RBD was first described in 1986 [31] in patients who were acting out their dreams. The behavior included moving their limbs, sleep talking, shouting, and screaming. In extreme cases, patients may hurt themselves and/or their spouses. Interestingly, if patients are woken-up by their bed-partner they will frequently describe a dream that explains their behavior.
RBD is often associated with synucleinopathies including Parkinson disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA); and in patients with these disorders, RBD frequently predates motor and cognitive deficits [23] . In postmortem studies of patients with RBD, neurodegeneration with abnormal deposition of a-synuclein affecting the pontomedullary brainstem nuclei is the most frequent finding [3, 7] .
Several studies have reported that RBD is frequent in patients with MSA [8, 10, 16, 22, 26, 27, 32, 33, 36, 37, 40, 41] , but its exact prevalence and whether RBD affects all patients with MSA is not known. Moreover, whether questionnaires alone are sufficient to diagnose RBD or if polysomnography showing abnormal muscle activation (i.e., lack of atonia) and vocalizations/motor behavior during REM sleep is required for the diagnosis is also unclear.
To answer these questions, we investigated the prevalence of RBD in patients with MSA prospectively enrolled in a multicenter study of academic medical centers in the US and Europe. We also performed a systematic review and meta-analysis of published studies on the prevalence of RBD in MSA.
Methods

Prevalence study
Cross-sectional multicenter study including patients with probable MSA [18] evaluated at the New York University School of Medicine (New York, NY), Mayo Clinic (Rochester, MN), Vanderbilt Medical Center (Nashville, TN), University of Michigan (Ann Arbor, MI), Stanford University School of Medicine (Stanford, CA) and the University Clinic of Navarra (Pamplona, Spain). Patients with both phenotypes (MSA-P and MSA-C) were included [18] . All patients underwent clinical and neurological evaluations by a board-certified neurologist. Institutional review boards at each participating site approved this study and written informed consent was obtained from all participants at enrollment. RBD was ascertained clinically, using validated questionnaires for RBD [13, 28] and with polysomnography. Polysomnography was performed using dedicated inputs for electroencephalogram (EEG, according to the 10-20 system: Fp1, Fp2, F3, F4, F7, F8, C3, C4, P3, P4, T3, T4, T5, T6, O1, O2, common reference), tibial and chin EMG, electrooculogram, oronasal flow, respiratory effort, oximetry, heart rate, body position, recording of sounds with microphone, and video recording. Sleep stages classification was performed following the current criteria [1] . RBD was diagnosed according to the Classification of Sleep Disorders [2] which requires detection of REM sleep without atonia and episodes of vocalization and/or motor behavior during REM sleep during polysomnography.
Systematic review and meta-analysis
This meta-analysis was prepared in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [25] . Articles on RBD and MSA were identified by searches of PubMed and EMBASE through September 1, 2014. Only articles in English were included. The following search strategy was used: (''Shy-Drager'' AND sleep) OR (''multiple system atrophy'' AND sleep) OR (''striatonigral degeneration'' AND sleep) OR (''olivopontocerebellar'' and sleep) OR (MSA AND sleep) OR (''autonomic failure'' AND sleep).
In addition, a manual search of bibliographies of included trials and related reviews was carried out for additional references. No unpublished data or data from abstracts were encountered or used. Articles were evaluated independently by two reviewers (J.A.P. and C.F.C.) who extracted the following data from each study: first author, year of publication, and prevalence of RBD in patients with definite, probable, or possible MSA according to the available criteria [17, 18, 29] . Studies were classified into those that ascertained the presence of RBD clinically (by means of questionnaires or history) and those that reported the prevalence of polysomnography-confirmed RBD. Case reports or case series (B5 patients) were not included.
Statistical analysis
The primary outcome measure was frequency of RBD in MSA as reported in prevalence (%).The pooled prevalence of RBD and 95 % confidence intervals were obtained by using a DerSimonian-Laird random-effects model with double arcsine transformation [11] . We ran a random-effect model rather than a fixed-effects model because of the high likelihood of heterogeneity between study variance. The heterogeneity of effect size estimates across studies was described with the I 2 index (with values of 25, 50, and 75 % considered low, moderate, and high, respectively) and Q statistic's p value [19] . Analyses were performed with Stata 13 (College Station, TX).
Sensitivity analysis was performed using the leave-oneout approach. Publication bias was ascertained by funnel plot, with an asymmetrical plot suggesting possible publication bias. Egger's test was used to assess funnel plot asymmetry. p \ 0.05 was considered as statistically significant. Six (14 %) patients had no signs of RBD in the polysomnography, of which 5 had MSA-C and 1 had MSA-P. These subjects were not taking benzodiazepines or any other medications known to disrupt REM sleep. Disease duration in these six patients was 6.7 ± 4.1 years.
Results
Prevalence
Two patients (4.7 %) had no REM sleep during the study so it was not possible to ascertain the presence of RBD. All patients reporting symptoms of RBD (except the two patients with no REM sleep) had signs of RBD during the sleep study. Two patients did not report symptoms of RBD but actually had polysomnography-confirmed RBD.
Meta-analysis results
As shown in Fig. 1 , the primary search strategy yielded 374 articles of which 12 met the inclusion criteria. Ten of this articles included prevalence on clinically suspected RBD and nine articles included prevalence on polysomnographyconfirmed RBD (Table 1) . Including the results of the present study, the summary prevalence of symptoms suggesting RBD in MSA was 73 % (95 % CI, 62-84 %) in a pooled sample of 324 subjects (Fig. 2a) . Between-study heterogeneity was high (80 %; p \ 0.001). The summary prevalence of polysomnography-confirmed RBD in MSA was 88 % (95 %, CI 79-94 %) in a pooled sample of 217 subjects (Fig. 2b) . Between-study heterogeneity was moderate (65 %; p \ 0.001). Sensitivity analysis showed unchanged results. There was no evidence of publication bias as the funnel plot was symmetrical and Egger's test was not significant (Supplementary Fig. 1 ).
Discussion
Our multicenter study confirms that RBD, as ascertained by polysomnography, is present in the vast majority of MSA patients (81 %). The results of the meta-analysis, in which the prevalence of polysomnography-confirmed RBD in a sample of 225 subjects with MSA was 88 %, are in keeping with the findings of our multicenter study.
The prevalence of clinically suspected RBD in MSA, as ascertained by questionnaires, was lower (83 % and 76.1 % in the multicenter study and 73 % in the meta-analysis) than the polysomnography-confirmed RBD. Conversely, patient-reported symptoms suggesting RBD accurately predicted the presence of RBD in polysomnography. Our results highlight that, although clinical recognition accurately diagnoses RBD in the majority of MSA patients, polysomnography is needed to diagnose RBD in some patients who do not report symptoms.
The pathways and nuclei involved in the pathophysiology of RBD are shown in Fig. 3 . Pontomedullary structures-including the magnocellular reticular formation (MCRF), sublaterodorsal (SLD), and pedunculopontine and laterodorsal (PPN/LDT) nuclei-are responsible for the atonia (i.e., lack of movement) during REM sleep [9] . The SLD has been identified in animals; the analog structure in humans is thought to be the subcoeruleus (SC) nucleus. Lesions in SLD/SC and MCRF (even unilaterally) is not yet known whether lesions in structures projecting to and from the magnocellular reticular formation, and lesioning the MCRF itself, affect atonia during REM sleep. GPi globus pallidus internus, LC locus coeruleus, LDT laterodorsal tegmental nucleus, LPT lateral pontine tegmentum, MCRF magnocellular reticular formation, PAG periaqueductal grey matter, PPN pedunculopontine nucleus, REM rapid eye movement, SC subcoeruleus nucleus and SLD sublaterodorsal nucleus are thought to eliminate atonia during REM sleep, leading to dream enacting behavior [20, 24, 35, 42] . Whether depletion of locus coeruleus (LC) neurons contributes to RBD is uncertain [12] .
Autopsy studies in MSA patients have shown depletion of cholinergic neurons in the PPN/LDN complex [6, 32] . The PPN may have, however, a modulatory role in REMrelated phenomena rather than a primary role for the atonia during REM sleep [4, 24] . Also in MSA, neurons of the PAG [5] and the LC are depleted [6] , although their specific role in RBD is unclear. In contrast to PD [15] , depletion of SC neurons has not been investigated in MSA.
The absence of RBD in some patients with MSA is intriguing. Of note, the prevalence of polysomnographyconfirmed RBD tended to be lower in MSA-C than in MSA-P (78 vs. 86 %; p = 0.49), and 4 of our 5 MSA patients with no RBD had MSA-C. However, the distribution of parkinsonian and cerebellar phenotypes in our sample was unusual as there were more MSA-C than P patients [30] . However, these patients also had longer disease duration, which suggests that RBD disappears as the disease progresses, indicating possible degeneration of brainstem nuclei that control REM sleep as previously suggested [39] . Conversely, the absence of RBD in some MSA patients may be indicative of worsening rigidity [38] . Additional longitudinal studies are needed to answer this.
In our study, 54 % of patients with MSA reported symptoms of RBD before the onset of motor deficits. This is in keeping with recent studies indicating that RBD represents a prodromal phase of PD, DLB and MSA [21, 23] . Further studies should determine whether the presence or absence of autonomic dysfunction in patients with idiopathic RBD predicts the development of a specific neurodegenerative disease.
In conclusion, RBD is present in up to 88 % of patients with MSA, including some patients recalling no symptoms. The prevalence of RBD in MSA is significantly higher than the percentage reported in patients with PD (50-60 %) [14, 34] . Our findings argue for the inclusion of RBD as a supportive clinical feature for MSA in forthcoming consensus criteria.
